

Summary of National Advisory Committee on Immunization statement of June 17, 2021

- For second doses, NACI recommends that:
 - Individuals who received a first dose of an mRNA vaccine (Pfizer-BioNTech, Moderna) should be offered the same mRNA product for their second dose. If the same product is not readily available, or the product used for the first dose is unknown, another mRNA vaccine is considered interchangeable and should be used to complete the series.
 - An mRNA vaccine **is now preferred** as the second dose for individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, based on emerging evidence of a potentially better immune response from this mixed vaccine schedule and to mitigate the potential risk of VITT associated with viral vector vaccines.
 - People who received two doses of AstraZeneca/COVISHIELD vaccine can rest assured that the vaccine provides good protection against infection and very good protection against severe disease and hospitalization.

Receiving a second vaccine dose for a two-dose schedule is essential to provide better and longer-term protection against COVID-19 for individuals and for the entire community.

NACI continues to closely monitor the evolving evidence on COVID-19 vaccines and will update recommendations as needed. To see the full statement, please visit [Recommendations on the use of COVID-19 vaccines](#).